CN101747321B - 吲哚-3-苄胺衍生物及制备方法和用途 - Google Patents
吲哚-3-苄胺衍生物及制备方法和用途 Download PDFInfo
- Publication number
- CN101747321B CN101747321B CN 200910157125 CN200910157125A CN101747321B CN 101747321 B CN101747321 B CN 101747321B CN 200910157125 CN200910157125 CN 200910157125 CN 200910157125 A CN200910157125 A CN 200910157125A CN 101747321 B CN101747321 B CN 101747321B
- Authority
- CN
- China
- Prior art keywords
- reaction
- indole
- compound
- methyl
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims description 38
- 238000006243 chemical reaction Methods 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- 230000000694 effects Effects 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 6
- -1 substituent arylamine Chemical class 0.000 claims abstract description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims abstract description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000012346 acetyl chloride Substances 0.000 claims abstract description 3
- 238000005886 esterification reaction Methods 0.000 claims abstract description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims abstract description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 38
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 31
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 29
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 12
- 239000002798 polar solvent Substances 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 150000003053 piperidines Chemical class 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 229910010082 LiAlH Inorganic materials 0.000 claims description 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 230000031709 bromination Effects 0.000 claims description 2
- 238000005893 bromination reaction Methods 0.000 claims description 2
- 239000007810 chemical reaction solvent Substances 0.000 claims description 2
- 229960001701 chloroform Drugs 0.000 claims description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 claims description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 150000002466 imines Chemical class 0.000 claims description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 2
- FJCCWUVWFDOSAU-UHFFFAOYSA-N n-benzylnitramide Chemical class [O-][N+](=O)NCC1=CC=CC=C1 FJCCWUVWFDOSAU-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims 2
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 claims 1
- 239000007868 Raney catalyst Substances 0.000 claims 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- 229910000564 Raney nickel Inorganic materials 0.000 claims 1
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 abstract description 14
- 238000012360 testing method Methods 0.000 abstract description 7
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract description 3
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract description 3
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical group NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 abstract description 3
- 239000003395 histamine H3 receptor antagonist Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 55
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 44
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 20
- 230000008569 process Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
- 239000007787 solid Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000003617 indole-3-acetic acid Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- WIHIUTUAHOZVLE-UHFFFAOYSA-N 1,3-diethoxypropan-2-ol Chemical compound CCOCC(O)COCC WIHIUTUAHOZVLE-UHFFFAOYSA-N 0.000 description 6
- BPCKWVMOXOYTQI-UHFFFAOYSA-N 4-(piperidin-1-ylmethyl)phenol Chemical compound C1=CC(O)=CC=C1CN1CCCCC1 BPCKWVMOXOYTQI-UHFFFAOYSA-N 0.000 description 6
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 6
- 230000006837 decompression Effects 0.000 description 6
- 238000003810 ethyl acetate extraction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 0 *c(cc1)ccc1O Chemical compound *c(cc1)ccc1O 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 238000000039 preparative column chromatography Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- YLMRZQGEWJVGBB-UHFFFAOYSA-N 4-(pyrrolidin-1-ylmethyl)phenol Chemical compound C1=CC(O)=CC=C1CN1CCCC1 YLMRZQGEWJVGBB-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000000742 histaminergic effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- PAMJENUKCYUKLC-UHFFFAOYSA-N 1-(4-nitrobenzyl)piperidine Chemical class C1=CC([N+](=O)[O-])=CC=C1CN1CCCCC1 PAMJENUKCYUKLC-UHFFFAOYSA-N 0.000 description 1
- GGRLKHMFMUXIOG-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CC(=O)OCC[N+](C)(C)C GGRLKHMFMUXIOG-UHFFFAOYSA-M 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ZPTVNYMJQHSSEA-UHFFFAOYSA-N 4-nitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C=C1 ZPTVNYMJQHSSEA-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000021061 dietary behavior Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000009449 neurobehavioral function Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Landscapes
- Indole Compounds (AREA)
Abstract
本发明提供一类吲哚-3-苄胺衍生物,通过取代的吲哚-3-羧酸与取代芳胺经缩合生成目的化合物,继续在碱性试剂作用下,与碘甲烷,乙酰氯,甲磺酰氯等反应,生成目的化合物,再经还原生成目的化合物;或由取代的吲哚-3-羧酸与取代苯酚经酯化反应而得。本发明在吲哚环的3-位用不同的类型,长度的连接链连接末端的苄胺片段,初步药理活性试验表明这些化合物有较好的H3受体拮抗活性,可制备治疗H3受体相关疾病的药物。本发明所用原料不仅来源广泛,易于制备,而且反应条件温和,各步收率高,操作简单,生产成本较低,适合工业化生产。本发明结构通式:
Description
技术领域
本发明属于有机化合物的合成,涉及吲哚-3-苄胺衍生物及制备方法和用途。
背景技术
1983年Arrang等通过药理实验在大鼠脑内发现了第3种组胺神经受体,简称H3受体。它是一种突触前自身受体,主要分布于中枢组胺能神经原、非组胺能神经原及自主神经系统,控制组胺的合成、释放与代谢并参与5-羟色胺、多巴胺、去甲肾上腺素、乙酰胆碱、γ-氨基丁酸等脑内多种神经递质的调控。可以调剂中枢神经系统的多种神经行为功能,诸如学习记忆、癫痫、自发运动饮食行为、觉醒与睡眠等。
组胺H3受体参与脑内多种神经递质的调控,其拮抗剂药物适应症可分为外周性和中枢性。外周适应症主要是鼻粘膜充血;中枢适应症包括嗜睡、肥胖、运动功能失调、心功能下降以及记忆功、认知功能减退等。因此针对H3受体,寻找和发现其特征性的拮抗剂可治疗一些与精神行为紊乱的疾病,如失眠、帕金森症、癫痫、焦虑症和老年痴呆等。
发明内容:
本发明目的是提供一类对H3受体有高度亲和力的吲哚-3-苄胺衍生物,本发明提供的吲哚-3-苄胺衍生物,具有以下结构通式:
其中:
NR1R2为哌啶、吡咯烷、吗啉、N-甲基哌嗪、二乙胺或乙胺中的任何一种;
R3为氢、甲基、乙酰基或磺酰基中的任何一种;
X为酰胺键、酯键或氨基中的任何一种,n=0,1,2,3。
本发明的另一个目的是提供吲哚-3-苄胺衍生物的制备方法,可以分别通过以下2条合成路线实现:
合成路线1:
(1)化合物II在溴化剂的作用下甲基经溴化得到化合物III,反应常用的溶剂有四氯化碳、二氯甲烷或三氯甲烷等,常用的溴化剂是N-溴代丁二酰亚胺(NBS),溴化亚铜等,反应温度在25-80℃;
(2)化合物III与仲胺(HNR1R2)反应得到对硝基苄胺化合物IV,反应在极性溶剂,如乙腈、二氯甲烷或1,2-二氯乙烷中进行,反应温度为50-85℃;
(3)化合物IV的硝基经还原得到对氨基苄胺化合物V,反应可以用二氯亚锡、Nanny镍或钯碳等还原剂在极性溶剂中还原,常用极性溶剂为甲醇或乙醇等,反应温度为30-80℃;
(4)吲哚-3-羧酸(化合物VI)在缩合剂的作用下与化合物V中的氨基发生酰化反应,得到目标化合物之一——酰胺化合物Ia,反应在二氯甲烷、四氢呋喃(THF)、N,N-二甲基甲酰胺(DMF)中进行,反应温度为20~80℃,常用缩合剂为N,N′-二环己基碳二亚胺(DCC)、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDC·HCl)或1-羟基苯并三唑(HOBt);
(5)化合物I a在碱性试剂的作用下,与碘甲烷、乙酰氯或甲磺酰氯等反应,生成目标化合物I b,碱性试剂为NaH、NaNH2、叔丁醇钾、乙醇钠或甲醇钠中的一种,反应常用溶剂为N,N-二甲基甲酰胺(DMF)或THF,温度控制在0~80℃;
(6)化合物I b经还原生成另一目标化合物——氨基化合物I c,常用的还原试剂有LiAlH4、NaBH4或KBH4等,常用的溶剂有二氯甲烷、四氢呋喃(THF)、乙腈或乙醇,反应温度为40~80℃。
合成路线2:
(1)化合物VII(对羟基苯甲醛)与不同的胺(HNR1R2)反应生成亚胺,再由NaBH4、KBH4等还原生成化合物VIII,反应在极性溶剂如甲醇、乙醇或乙腈中进行,反应温度控制在0~50℃;
(2)吲哚-3-羧酸(化合物VI)在缩合剂的作用下与化合物VIII中的羟基发生酯化反应,得到目标化合物I d,反应在二氯甲烷、四氢呋喃(THF)、N,N-二甲基甲酰胺(DMF)中进行,反应温度为20~80℃,常用缩合剂为N,N′-二环己基碳二亚胺(DCC),1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDC·HCl),1-羟基苯并三唑(HOBt)。
本发明所述的吲哚-3-苄胺衍生物的生理可接受的盐,所用的盐包括无机酸或有机酸盐,其中无机酸选自盐酸,硫酸或氢溴酸或磷酸;有机酸选自乙酸,丙二酸,马来酸,乳酸或甲磺酸。
本发明的再一个目的是提供吲哚-3-苄胺衍生物在制备治疗H3受体相关疾病药物中的应用。H3受体相关疾病包括嗜睡、肥胖、注意多动缺陷障碍、认知功能障碍等疾病。
实验证实吲哚-3-苄胺衍生物与组胺H3受体有很高的亲和力,可对H3受体产生拮抗作用,具有较好的组胺H3受体拮抗活性,其活性强度与H3受体内源性结合物组胺相当或更好。
本发明的特点是在吲哚环的3-位用不同的类型,长度的连接链连接末端的苄胺片段。这是一类结构全新的化合物,初步药理活性试验表明这些化合物有较好的H3受体拮抗活性。苯发明所用原料不仅来源广泛,易于制备,而且反应条件温和,各步收率高,操作简单,生产成本较低,适合工业化生产。
具体实施方案
本发明结合实施例作进一步的说明。以下实施例仅说明本发明,而不是以任何方式限制本发明。
实施例1:1-溴甲基-4-硝基苯的制备(III-1)
将1g(7.3mmol)对硝基甲苯溶解在20ml四氯化碳中,加入1.43g N-溴代丁二酰亚胺(NBS),并加入催化量的过氧苯甲酰,搅拌并加热至回流,反应5小时。反应完后,冷却过滤,收集滤液,减压回收溶剂,得到1.46g淡黄色晶体,收率93%,熔点98℃(文献值98-100℃)。
实施例2:1-(4-硝基苄基)哌啶的制备(IV-1)
将1g(0.47mmol)1-溴甲基-4-硝基苯溶于15ml乙腈,室温下缓慢滴加0.92ml(0.94mmol)哌啶和5ml乙腈的混合溶液,滴加完后加热至70℃反应2小时。反应完后减压回收溶剂,加入冰水后,滴加2N的HCl调pH至3~4后,用乙酸乙酯萃取,取水层,加氨水调pH至10,再用乙酸乙酯萃取,取有机层,水洗、饱和氯化钠洗涤后,无水硫酸钠干燥,回收溶剂,得到黄色油状液体0.86g,收率85%。
实施例3:4-(哌啶-1-甲基)苯胺的制备(V-1)
将500mg(2.27mmol)1-(4-硝基苄基)哌啶溶解在15ml乙醇中,加入氯化亚锡1.53g(6.81mmol),加热至回流,反应2小时。反应完后减压回收溶剂,加入冰水,用10%NaOH溶液调pH至10,出现大量固体混悬物。过滤,收集滤液,用乙酸乙酯萃取,取有机层,水洗、饱和氯化钠洗涤后,无水硫酸钠干燥,回收溶剂。通过柱层析(乙酸乙酯∶石油醚∶三乙胺=20∶20∶1)分离,得到306mg淡黄色固体,收率71%,熔点119-121℃。
实施例4:2-(1H-吲哚-3-)-N-(4-(吡咯烷-1-甲基)苯基)乙酰胺的制备(I a-1)
将300mg(1.71mmol)吲哚-3-乙酸溶解于8ml二氯甲烷和2mlTHF的混合溶剂中,加入423mg(2.05mmol)DCC,在室温下搅拌1小时。再加入4-(吡咯烷-1-甲基)苯胺301mg(1.71mmol),在室温下反应4小时。反应完全后,加硅藻土过滤,取滤液。用二氯甲烷萃取,,取有机层,水洗、饱和氯化钠洗涤后,无水硫酸钠干燥,回收溶剂,经柱层析(石油醚∶乙酸乙酯∶三乙胺=20∶30∶1)分离可得淡黄色粉末231mg,收率为24.4%。熔点为185-187℃。
1HNMR(500MHz,CDCl3):δ8.52(s,1H,H-1),7.63(d,J=8.0Hz,1H,H-4),7.43(m,2H,H-7,-CONH),7.29(m,3H,H-3’,H-5’,H-6),7.24(m,4H,H-2,H-5,H-2’,H-6’),3.89(s,2H,-CH 2N-),3.54(s,2H,-CH 2CO-),2.45-2.46(m,4H,H-“pyrrolidine”),1.73-2.05(m,4H,H-“pyrrolidine”);
IR(KBr,cm-1):3293,3132,2968,2921,2811,1657,1605,1535,1411,1126,834,738。
实施例5:2-(1H-吲哚-3-)-N-(4-(哌啶-1-甲基)苯基)乙酰胺的制备(I a-2)
操作过程同实施例4,只是用4-(哌啶-1-甲基)苯胺代替4-(吡咯烷-1-甲基)苯胺,得白色固体,收率为28.1%,熔点177-178℃。
1HNMR(500MHz,CDCl3):8.48(s,1H,H-1),7.63(d,J=8.4Hz,1H,H-4),7.44(m,2H,H-7,-CONH),7.28(m,3H,H-3’,H-5’,H-6),7.15-7.24(m,4H,H-2,H-5,H-2’,H-6’),3.89(s,2H,-CH 2N-),3.42(s,2H,-CH 2CO-),2.35(m,4H,H-“piperidine”),1.52-1.57(m,4H,H-“piperidine”),1.40-1.41(m,2H,H-“piperidine”);
IR(KBr,cm-1)3297,2936,2798,1660,1606,1534,1412,1344,1105,831,739。
实施例6:2-(1H-吲哚-3-)-N-(4-(吗啉-1-甲基)苯基)乙酰胺的制备(I a-3)
操作过程同实施例4,只是用4-(吗啉-1-甲基)苯胺代替4-(吡咯烷-1-甲基)苯胺,得白色固体,熔点:128-130℃,收率为23.2%。
1HNMR(500MHz,CDCl3):δ8.34(s,1H,H-1),7.63(d,J=8.0Hz,1H,H-4),7.45(d,J=7.5Hz,1H,H-7),7.39(s,1H,-CONH),7.30(m,3H,H-3’,H-5’,H-6),7.23(m,4H,H-2,H-5,H-2’,H-6’),3.90(s,2H,-CH2N-),3.68(t,4H,J=4.5Hz,H-“morpholine”),3.41(s,2H,-CH2CO-),2.40(t,4H,J=4.0Hz,H-“morpholine”)。
实施例7:N-(4-((二乙胺基)甲基)苯基)-2-(1H-吲哚-3-)乙酰胺的制备(I a-4)
操作过程同实施例4,只是用4-((二乙胺基)甲基)苯胺代替4-(吡咯烷-1-甲基)苯胺,得淡黄色固体,熔点:133-135℃,收率为23.9%。
1HNMR(500MHz,CDCl3):δ8.30(s,1H,H-1),7.64(d,J=7.5Hz,1H,H-4),7.44(d,J=7.5Hz,1H,H-7),7.36(s,1H,-CONH),7.28(m,3H,H-3’,H-5’,H-6),7.23(m,4H,H-2,H-5,H-6,H-2’,H-6’),3.90(s,2H,-CH 2N-),3.49(s,2H,-CH 2CO-),2.52(m,4H,-CH 2CH3),1.01(t,6H,J=7.5Hz,-CH2CH 3)。
IR(KBr,cm-1):3291,3128,2923,2854,1659,1605,1535,1413,1314,1265,836,741。
实施例8:3-(1H-吲哚-3-)-N-(4-(吗啉甲基)苯基)丙酰胺的制备(I a-5)
操作过程同实施例4,只是用4-(吗啉-1-甲基)苯胺代替4-(吡咯烷-1-甲基)苯胺,用吲哚-3-丙酸代替吲哚-3-乙酸,得白色固体,熔点:114-116℃,收率为41.2%。
1HNMR(500MHz,CDCl3):δ8.05(s,1H,H-1),7.64(d,J=7.5Hz,1H,H-4),7.38(d,J=8.0Hz,1H,H-7),7.32(d,2H,J=8.0Hz,H-5,H-6),7.23(d,2H,J=8.0Hz,H-3’,H-5’),7.15(t,1H,J=7.5Hz,H-2),7.04(s,2H,H-2’,H-6’),3.71(m,4H,H-“piperidine”),3.46(s,2H,-CH 2N-),3.22(t,2H,J=7.0Hz,-CH 2CH2CO-),2.76(t,2H,J=7.5Hz,-CH2CH 2CO-),2.42(m,4H,H-“piperidine”),1.65(m,2H,H-“piperidine”)。
实施例9:3-(1H-吲哚-3-)-N-(4-(吡咯烷甲基)苯基)丙酰胺的制备(I a-6)
操作过程同实施例4,只是用吲哚-3-丙酸代替吲哚-3-乙酸,得黄色固体,收率为36.5%。
1HNMR(500MHz,CDCl3):δ8.26(s,1H,H-1),7.63(d,J=7.5Hz,1H,H-4),7.36(d,J=7.5Hz,1H,H-7),7.31(d,2H,J=8.0Hz,H-2’,H-6’),7.23(d,4H,J=8.0Hz,H-2,H-6,H-3’,H-5’),7.14(t,1H,J=7.5Hz,H-5),6.97(s,1H,-CONH-),3.58(s,2H,-CH 2N-),3.20(t,2H,J=7.5Hz,-CH 2CH2CO-),2.74(t,2H,J=7.5Hz,-CH2CH 2CO-),2.54(m,4H,H-“pyrrolidine”),1.79(m,4H,H-“pyrrolidine”)。
实施例10:3-(1H-吲哚-3-)-N-(4-(哌啶甲基)苯基)丙酰胺的制备(I a-7)
操作过程同实施例4,只是用4-(哌啶-1-甲基)苯胺代替4-(吡咯烷-1-甲基)苯胺,用吲哚-3-丙酸代替吲哚-3-乙酸,得白色固体,熔点:152-154℃,收率为43.5%。
1HNMR(500MHz,CDCl3):δ8.05(s,1H,H-1),7.63(d,J=10.5Hz,1H,H-4),7.36(d,J=10.0Hz,1H,H-7),7.28(d,2H,J=10.5Hz,H-5,H-6),7.21(m,3H,H-2’,H-6’,-CONH-),7.14(t,1H,J=9.0Hz,H-2),7.02(d,2H,J=12.0Hz,H-3’,H-5’),3.39(s,2H,-CH 2N-),3.21(t,2H,J=8.5Hz,-CH 2CH2CO-),2.74(t,2H,J=8.5Hz,-CH2CH 2CO-),2.33(m,4H,H-“piperidine”),1.56(m,4H,H-“piperidine”),1.41(m,2H,H-“piperidine”)。
实施例11:N-(4-((二乙胺基)甲基)苯基)-3-(1H-吲哚-3-)丙酰胺的制备(I a-8)
操作过程同实施例4,只是用4-((二乙胺基)甲基)苯胺代替4-(吡咯烷-1-甲基)苯胺,用吲哚-3-丙酸代替吲哚-3-乙酸,得淡黄色固体,收率为39.5%。
1HNMR(500MHz,CDCl3):δ8.30(s,1H,H-1),7.64(d,J=7.5Hz,1H,H-4),7.44(d,J=7.5Hz,1H,H-7),7.36(s,1H,-CONH),7.28(m,3H,H-3’,H-5’,H-6),7.23(m,4H,H-2,H-5,H-6,H-2’,H-6’),3.50(s,2H,-CH 2N-),3.19(t,2H,J=7.0Hz,-CH 2CH2CO-),2.73(t,2H,J=7.0Hz,-CH2CH2CO-),2.53(m,4H,-CH 2CH3),1.05(m,6H,-CH2CH 3)。
实施例12:N-(4-(哌啶-1-甲基)苯基)-1H-吲哚-3-甲酰胺的制备(I a-9)
操作过程同实施例4,只是用4-(哌啶-1-甲基)苯胺代替4-(吡咯烷-1-甲基)苯胺,用吲哚-3-甲酸代替吲哚-3-乙酸,得黄色固体,收率为19.8%。
1HNMR(500MHz,CDCl3):δ8.96(s,1H,H-1),8.07(t,J=3.5Hz,1H,H-4),7.84(s,1H,H-7),7.28(d,2H,J=10.5Hz,H-5,H-6),7.21(m,3H,H-2’,H-6’,-CONH-),7.14(t,1H,J=9.0Hz,H-2),7.02(d,2H,J=12.0Hz,H-3’,H-5’),3.39(s,2H,-CH 2N-),3.21(t,2H,J=8.5Hz,-CH 2CH2CO-),2.74(t,2H,J=8.5Hz,-CH2CH 2CO-),2.33(m,4H,H-“piperidine”),1.56(m,4H,H-“piperidine”),1.41(m,2H,H-“piperidine”)。
实施例13:2-(1-甲基-1H-吲哚-3-)-N-(4-(吗啉甲基)苯基)乙酰胺的制备(I b-1)
将2-(1H-吲哚-3-)-N-(4-(吗啉-1-甲基)苯基)乙酰胺100mg(0.29mmol)溶于5.0mlDMF中,冰浴冷却到0℃,加入NaH 15mg(0.38mmol)于搅拌0.5小时后,滴加溶于2mlDMF的碘甲烷0.03ml(0.58mmol),撤去冰浴,室温反应2小时。反应完后,用二氯甲烷提取,分别用水、饱和食盐水洗涤,用无水Na2SO4干燥,减压回收溶剂。通过制备柱层析(乙酸乙酯∶三乙胺=40∶1)分离最终可得21mg黄色粘稠物,收率为20.2%。
1HNMR(500MHz,CDCl3):δ7.61(d,J=8.0Hz,1H,H-4),7.47(s,1H,-CONH),7.38(d,J=8.5Hz,1H,H-7),7.31(m,3H,H-3’,H-5’,H-6),7.20(m,3H,H-5,H-2’,H-6’),7.07(s,1H,H-2),3.87(s,2H,-CH2N-),3.82(s,3H,-CH3)3.68(t,4H,J=5.0Hz,H-“morpholine”),3.41(s,2H,-CH2CO-),2.40(t,4H,J=4.0Hz,H-“morpholine”)。
实施例14:N-(2-(1H-吲哚-3-)乙基)-4-(吡咯烷-1-甲基)苯胺的制备(I c-1)
将2-(1H-吲哚-3-)-N-(4-(吡咯烷-1-甲基)苯基)乙酰胺80mg(0.24mmol)溶于8.0ml无水THF中,加入LiAlH427.4mg(0.72mmol),在80℃加热回流4小时。反应完后冷却到室温,再滴加0.5ml水破坏未反应的LiAlH4,过滤,浓缩滤液,用乙酸乙酯提取,分别用水、饱和食盐水洗涤,用无水Na2SO4干燥,减压回收溶剂。通过制备柱层析(乙酸乙酯∶石油醚∶三乙胺=20∶20∶1)分离最终可得50.1mg黄色液体,收率为65.4%。
1HNMR(500MHz,CDCl3):δ8.13(s,1H,H-1),7.64(d,1H,J=10.0Hz,H-4),7.40(d,1H,J=9.5Hz,H-7),7.23(t,1H,J=9.0Hz,H-6),7.15(m,3H,H-5,H-3’,H-5’),7.06(d,1H,J=2.5Hz,H-2),6.58(d,2H,J=10.5Hz,H-2’,H-6’),3.56(s,2H,-CH 2N-),3.49(t,2H,J=7.5Hz,-CH2CH 2NH-),3.11(t,2H,J=7.5Hz,-CH 2CH2NH-),2.56(m,4H,H-“pyrrolidine”),1.80(m,4H,H-“pyrrolidine”)。
实施例15:N-(2-(1H-吲哚-3-)乙基)-4-(吗啉-1-甲基)苯胺的制备(I c-2)
操作过程同实施例14,只是用2-(1H-吲哚-3-)-N-(4-(吗啉-1-甲基)苯基)乙酰胺代替2-(1H-吲哚-3-)-N-(4-(吡咯烷-1-甲基)苯基)乙酰胺,得黄色液体,收率为59.8%。
1HNMR(500MHz,CDCl3):δ8.25(s,1H,H-1),7.65(d,1H,J=7.0Hz,H-4),7.37(d,1H,J=7.0Hz,H-7),7.23(t,1H,J=9.0Hz,H-6),7.17(m,3H,H-5,H-3’,H-5’),7.03(d,1H,J=2.0Hz,H-2),6.60(d,2H,J=7.5Hz,H-2’,H-6’),3.74(t,4H,J=4.5Hz,H-“morpholine”),3.50(t,2H,J=7.0Hz,-CH2CH 2NH-),3.43(s,2H,-CH 2N-),3.12(t,2H,J=6.5Hz,-CH 2CH2NH-),2.46(m,4H,H-“morpholine”)。
实施例16:N-(2-(1H-吲哚-3-)乙基)-4-(哌啶-1-甲基)苯胺的制备(I c-3)
操作过程同实施例14,只是用2-(1H-吲哚-3-)-N-(4-(哌啶-1-甲基)苯基)乙酰胺代替2-(1H-吲哚-3-)-N-(4-(吡咯烷-1-甲基)苯基)乙酰胺,得黄色液体,收率为63.2%。
1HNMR(500MHz,CDCl3):δ8.47(s,1H,H-1),7.69(d,1H,J=7.5Hz,H-4),7.42(d,1H,J=7.5Hz,H-7),7.28(t,1H,J=7.5Hz,H-6),7.20(m,3H,H-5,H-3’,H-5’),7.07(s,1H,H-2),6.63(d,2H,J=8.0Hz,H-2’,H-6’),3.54(t,2H,J=6.5Hz,-CH2CH 2NH-),3.45(s,2H,-CH 2N-),3.16(t,2H,J=6.0Hz,-CH 2CH2NH-),2.45(m,4H,H-“piperidine”),1.64(m,4H,H-“piperidine”),1.49(m,4H,H-“piperidine”)。
实施例17:N-(2-(1H-吲哚-3-)乙基)-4-((二乙胺)甲基)苯胺的制备(I c-4)
操作过程同实施例14,只是用N-(4-((二乙胺基)甲基)苯基)-2-(1H-吲哚-3-)乙酰胺代替2-(1H-吲哚-3-)-N-(4-(吡咯烷-1-甲基)苯基)乙酰胺,得黄色液体,收率为70.8%。
1HNMR(500MHz,CDCl3):δ8.14(s,1H,H-1),7.68(d,1H,J=8.0Hz,H-4),7.42(d,1H,J=7.5Hz,H-7),7.28(t,1H,J=8.0Hz,H-6),7.19(m,3H,H-5,H-3’,H-5’),7.10(d,1H,J=2.0Hz,H-2),6.63(d,2H,J=7.5Hz,H-2’,H-6’),3.53(t,2H,J=6.0Hz,-CH2CH 2NH-),3.15(t,2H,J=6.0Hz,-CH 2CH2NH-),2.57(m,4H,-CH 2CH3),2.10(s,2H,-CH 2N-),1.12(m,6H,-CH2CH 3)。
实施例18:N-(3-(1H-吲哚-3-)丙基)-4-(吗啉甲基)苯胺的制备(I c-5)
操作过程同实施例14,只是用N-(4-((二乙胺基)甲基)苯基)-2-(1H-吲哚-3-)乙酰胺代替2-(1H-吲哚-3-)-N-(4-(吡咯烷-1-甲基)苯基)乙酰胺,得黄色液体,收率为70.8%。
1HNMR(500MHz,CDCl3):δ8.05(s,1H,H-1),7.62(d,1H,J=8.0Hz,H-4),7.42(d,1H,J=8.0Hz,H-7),7.22(t,1H,J=7.5Hz,H-6),7.14(m,3H,H-5,H-3’,H-5’),6.98(d,1H,J=2.5Hz,H-2),6.56(d,2H,J=7.5Hz,H-2’,H-6’),3.72(t,4H,J=4.5Hz,H-“morpholine”),3.40(s,2H,-CH 2N-),3.22(t,2H,J=6.0Hz,-CH2CH2CH 2NH-),2.91(t,2H,J=7.5Hz,-CH 2CH2CH2NH-),2.44(m,4H,H-“morpholine”),2.08(m,2H,-CH2CH 2CH2NH-)。
实施例19:N-((1H-吲哚-3-)甲基)-4-(哌啶-1-甲基)苯胺的制备(I c-6)
操作过程同实施例14,只是用N-(4-(哌啶-1-甲基)苯基)-1H-吲哚-3-甲酰胺代替2-(1H-吲哚-3-)-N-(4-(吡咯烷-1-甲基)苯基)乙酰胺,得黄色液体,收率为65.9%。
1HNMR(500MHz,CDCl3):δ8.22(s,1H,H-1),7.69(d,1H,J=8.0Hz,H-4),7.40(d,1H,J=8.0Hz,H-7),7.25(t,1H,J=8.0Hz,H-5),7.19(d,J=2.5Hz,2H,H-2),7.16(m,2H,H-3’,H-5’)7.10(t,J=4.0Hz,1H,H-6),6.68(d,2H,J=8.0Hz,H-2’,H-6’),4.48(s,2H,-CH 2NH-),3.46(s,2H,-CH 2N-),2.44(m,4H,H-“piperidine”),1.64(m,4H,H-“piperidine”),1.44(m,2H,H-“piperidine”)。
实施例20:4-(哌啶-1-基甲基)苯酚的制备(VIII)
对羟基苯甲醛2.58g(19.0mmol)溶于10.00ml的甲醇中,在冰浴下滴加哌啶4.0ml(40.50mmol)和甲醇5.0ml的混合溶液,在室温下反应0.5~1小时。用TLC检测反应液中无对羟基苯甲醛后,分批加入NaBH4 1.00g(26.40mmol),控制温度在常温。TLC检测反应完全后,将溶剂蒸干,加入冰水后,滴加2N的HCl调pH至3~4后,用乙酸乙酯萃取,取水层,加氨水调PH至碱性,再用乙酸乙酯萃取,取有机层,水洗、饱和氯化钠洗涤后,无水硫酸钠干燥,回收溶剂,得到白色固体3.21g,收率80%,m.p.133~135℃。
实施例21:4-(哌啶-1-甲基)苯基-2-(1H-吲哚-3-)乙酯的制备(I d-1)
将吲哚-3-乙酸250mg(1.43mmol)溶于10ml二氯甲烷和2mlTHF的无水混合溶液中,加入295mg(1.43mmol)DCC和175mg(1.43mmol)DMAP后,加入245mg(1.43mmol)4-(哌啶-1-基甲基)苯酚,室温反应6小时。反应完后加水,过滤,取滤液。用二氯甲烷萃取,取油层,分别用水、饱和食盐水洗涤,用无水Na2SO4干燥,减压回收溶剂。通过制备柱层析(乙酸乙酯∶石油醚∶三乙胺=10∶10∶0.5)分离最终可得138mg黄色粘稠物,收率为28.1%。
1HNMR(500MHz,CDCl3):δ8.43(s,1H,H-1),7.72(d,1H,J=7.5Hz,H-4),7.36(d,1H,J=8.5Hz,H-7),7.30(d,2H,J=8.5Hz,H-3’,H-5’),7.24(m,2H,H-2,H-6),7.18(t,1H,J=7.0Hz,H-5),7.02(d,2H,J=8.0Hz,H-2’,H-6’),4.02(s,2H,-CH 2N-),3.61(s,2H,-CH 2CO-),2.38(m,4H,H-“piperidine”),1.60(m,4H,H-“piperidine”),1.44(m,2H,H-“piperidine”)。
实施例22:4-(吡咯烷-1-甲基)苯基-2-(1H-吲哚-3-)乙酯的制备(I d-2)
操作过程同实施例21,只是用4-(吡咯烷-1-基甲基)苯酚代替4-(哌啶-1-基甲基)苯酚,得黄色液体,收率为24.7%。
1HNMR(500MHz,CDCl3):δ8.32(s,1H,H-1),7.71(d,1H,J=7.5Hz,H-4),7.37(d,1H,J=7.5Hz,H-7),7.31(d,2H,J=8.5Hz,H-3’,H-5’),7.23(m,2H,H-2,H-6),7.17(t,1H,J=7.0Hz,H-5)7.01(d,2H,J=9.0Hz,H-2’,H-6’),4.01(s,2H,-CH 2N-),3.62(s,2H,-CH 2CO-),2.55(m,4H,H-“pyrrolidine”),1.80(m,4H,H-“pyrrolidine”)。
实施例23:4-(吗啉-1-甲基)苯基-2-(1H-吲哚-3-)乙酯的制备(I d-3)
操作过程同实施例21,只是用4-(吗啉-1-基甲基)苯酚代替4-(哌啶-1-基甲基)苯酚,得黄色液体,收率为30.5%。
1HNMR(500MHz,CDCl3):δ8.18(s,1H,H-1),7.71(d,1H,J=10.0Hz,H-4),7.38(d,1H,J=9.5Hz,H-7),7.31(d,2H,J=10.5Hz,H-3’,H-5’),7.24(m,2H,H-2,H-6),7.18(t,1H,J=7.0Hz,H-5),7.02(d,2H,J=10.5Hz,H-2’,H-6’),4.01(s,2H,-CH 2N-),3.70(t,4H,J=6.0Hz,H-morpholine),3.46(s,2H,-CH 2CO-),2.43(t,4H,J=5.5Hz,H-“morpholine”)。
实施例24:4-(吡咯烷-1-甲基)苯基-3-(1H-吲哚-3-)丙酯的制备(I d-4)
操作过程同实施例21,只是用4-(吡咯烷-1-基甲基)苯酚代替4-(哌啶-1-基甲基)苯酚,用吲哚-3-丙酸代替吲哚-3-乙酸,得白色固体,熔点:98-100℃,收率为50.6%。
1HNMR(500MHz,CDCl3):δ8.05(s,1H,H-1),7.70(d,1H,J=8.0Hz,H-4),7.42(d,1H,J=8.5Hz,H-7),7.35(d,2H,J=8.5Hz,H-3’,H-5’),7.27(t,1H,J=7.5Hz,H-6),7.19(t,1H,J=7.5Hz,H-5),7.11(s,1H,H-2),7.00(d,2H,J=1.0Hz,H-2’,H-6’),3.63(s,2H,-CH 2N-),3.28(t,2H,J=7.5Hz,-CH 2CH2CO-),3.01(t,2H,J=1.0Hz,-CH2CH 2CO-),2.54(m,4H,H-“pyrrolidine”),1.83(m,4H,H-“pyrrolidine”)。
实施例25:4-(哌啶-1-甲基)苯基-3-(1H-吲哚-3-)丙酯的制备(I d-5)
操作过程同实施例21,只是用吲哚-3-丙酸代替吲哚-3-乙酸,得白色固体,熔点:89-90℃,收率为48.3%。
1HNMR(500MHz,CDCl3):δ8.01(s,1H,H-1),7.66(d,1H,J=7.5Hz,H-4),7.38(d,1H,J=8.0Hz,H-7),7.30(d,2H,J=8.5Hz,H-3’,H-5’),7.23(t,1H,J=7.0Hz,H-6),7.16(t,1H,J=8.0Hz,H-5),7.08(s,1H,H-2),6.96(d,2H,J=7.5Hz,H-2’,H-6’),3.73(m,4H,H-“piperidine”),3.43(s,2H,-CH 2N-),3.22(t,2H,J=7.0Hz,-CH 2CH2CO-),2.76(t,2H,J=7.5Hz,-CH2CH 2CO-),2.4(m,4H,H-“piperidine”),1.65(m,2H,H-“piperidine”)。
实施例26:4-(吗啉-1-甲基)苯基-3-(1H-吲哚-3-)丙酯的制备(I d-6)
操作过程同实施例21,只是用4-(吗啉-1-基甲基)苯酚代替4-(哌啶-1-基甲基)苯酚,用吲哚-3-丙酸代替吲哚-3-乙酸,得黄色液体,收率为45.7%。
1HNMR(500MHz,CDCl3):δ8.12(s,1H,H-1),7.66(d,1H,J=8.0Hz,H-4),7.38(d,J=8.5Hz,1H,H-7),7.31(d,2H,J=7.5Hz,H-3’,H-5’),7.22(t,1H,J=8.0Hz,H-6),7.15(t,1H,J=7.5Hz,H-5),7.08(s,1H,H-2),6.97(d,2H,J=6.5Hz,H-2’,H-6’),3.74(m,4H,H-“morpholine”),3.47(s,2H,-CH 2N-),3.24(t,2H,J=7.5Hz,-CH 2CH2CO-),2.98(t,2H,J=7.5Hz,-CH2CH 2CO-),2.44(m,4H,H-“morpholine”)。
实施例27:4-((二乙胺)甲基)苯基-3-(1H-吲哚-3-)丙酯的制备(I d-7)
操作过程同实施例21,只是用4-((二乙胺)甲基)苯酚代替4-(哌啶-1-基甲基)苯酚,用吲哚-3-丙酸代替吲哚-3-乙酸,得黄色液体,收率为51.2%。
1HNMR(500MHz,CDCl3):δ8.04(s,1H,H-1),7.66(d,1H,J=8.0Hz,H-4),7.38(d,1H,J=8.0Hz,H-7),7.32(d,2H,J=7.5Hz,H-3’,H-5’),7.23(t,1H,J=6.0Hz,H-6),7.16(t,1H,J=7.5Hz,H-5),7.08(s,1H,H-2),6.96(d,2H,J=7.5Hz,H-2’,H-6’),3.54(s,2H,-CH 2N-),3.25(t,2H,J=8.0Hz,-CH 2CH2CO-),2.98(t,2H,J=7.5Hz,-CH2CH 2CO-),2.55(m,4H,-NCH 2CH3),1.05(t,4H,J=7.5Hz,-NCH2CH 3)。
实施例28:4-(哌啶-1-甲基)苯基-1H-吲哚-3-甲酯的制备(I d-8)
操作过程同实施例21,只是用吲哚-3-甲酸代替吲哚-3-乙酸,得白色固体,熔点:145-150℃,收率为27.1%。
1HNMR(500MHz,CDCl3):δ8.31(m,1H,H-1),8.08(s,1H,H-4),7.50(m,1H,H-7),7.43(d,2H,J=8.0Hz,H-3’,H-5’),7.37(m,2H,H-5),7.25(d,2H,J=8.0Hz,H-2’,H-6’),7.16(d,J=8.5Hz,1H,H-6)6.72(d,1H,J=9.0Hz,H-2),3.56(s,2H,-CH 2N-),2.47(m,4H,H-“piperidine”),1.66(m,4H,H-“piperidine”),1.49(m,2H,H-“piperidine”)。
实施例29:吲哚-3-苄胺衍生物对H3受体的体外抑制作用
1.实验材料:
细胞株:HEK293细胞,CHO细胞。
培养基:DMEM培养基加10%小牛血清。
药物及配制:药物为上述合成的吲哚-3-苄胺衍生物,药物溶于DMSO。
2.实验方法:
(1).细胞培养和稳定表达细胞株构建:用于实验的细胞株主要有HEK293和CHO细胞。这二种细胞均用DMEM培养基加10%FBS。细胞转染或共转染受体表达载体和报告基因表达载体用Lipofectamine-2000.转染24小时后,加入G418,HEK293细胞为800μg/ml,而CHO细胞为600μg/ml,三-四天换一次含G418新鲜培养基。二周后,可见明显的细胞群落,挑20-30个细胞群落扩增后,用功能性实验或流式细胞分析受体细胞表面表达及报告基因的效果,把高表达细胞株或功能测试良好的细胞株扩增后冻存,用于药物筛选、功能活性测试和结合活性测试等实验。
(2).细胞内cAMP浓度的检测:在组胺H3受体和CRE-Luciferase稳定表达细胞株细胞中加Foskolin(终浓度10μM)和不同浓度的化合物,培养5h后裂解细胞检测荧光素酶活性,活性大小对应cAMP浓度高低。
(3).萤光素酶活性的测定:细胞水平高通量筛选模型和用cAMP响应元件(CRE)控制下的萤光素酶表达载体检测cAMP,最后均需测定萤光素酶活性。萤光素酶活性测定用Promega试剂盒,按试剂盒要求,在反应结束后,加入溶胞缓冲液,立即用Topcounter或化学发光仪读出RLU(相对光强度单位)。
3.实验结果:
在此类吲哚-3-苄胺衍生物中部分化合物有较好的H3受体拮抗活性,其活性强度与H3受体内源性结合物组胺相当或更好。下表列举其中几个化合物的活性数据:
Claims (4)
2.根据权利要求1所述的吲哚-3-苄胺衍生物的制备方法,其特征是通过以下步骤实现:
(1)化合物Ⅱ在溴化剂的作用下甲基经溴化得到化合物Ⅲ,反应选用的溶剂为四氯化碳、二氯甲烷或三氯甲烷,溴化剂选用N-溴代丁二酰亚胺或溴化亚铜,反应温度在25-80℃;
(2)化合物Ⅲ与HNR1R2反应得到对硝基苄胺化合物Ⅳ,反应在极性溶剂中进行,反应温度为50-85℃;
(3)化合物Ⅳ的硝基经还原得到对氨基苄胺化合物Ⅴ,还原剂选用二氯亚锡、Raney镍或钯碳,在极性溶剂中还原,反应温度为30-80℃;
(4)化合物VI在缩合剂的作用下与化合物Ⅴ中的氨基发生酰化反应,得到目标化合物Ⅰa,反应在二氯甲烷、四氢呋喃或N,N-二甲基甲酰胺中进行,反应温度为20~80℃,缩合剂选用N,N′-二环己基碳二亚胺、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐或1-羟基苯并三唑;
(5)化合物Ⅰa在碱性试剂的作用下,与碘甲烷、乙酰氯或甲磺酰氯反应,生成目标化合物Ⅰb,碱性试剂选用NaH、NaNH2、叔丁醇钾、乙醇钠或甲醇钠中的一种,反应溶剂为N,N-二甲基甲酰胺或四氢呋喃,温度控制在0~80℃;
(6)化合物Ⅰb经还原生成目标化合物Ⅰc,还原剂选用LiAlH4、NaBH4或KBH4,溶剂选用二氯甲烷、四氢呋喃或乙腈或乙醇,反应温度为40~80℃;
合成路线:
其中:NR1R2、R3、n的定义与权利要求1相同。
3.根据权利要求1所述的吲哚-3-苄胺衍生物的制备方法,其特征是通过以下步骤实现:
(1)化合物Ⅶ与HNR1R2反应生成亚胺,再由NaBH4或KBH4还原生成化合物Ⅷ,反应在极性溶剂中进行,反应温度控制在0~50℃;
(2)化合物VI在缩合剂的作用下与化合物Ⅷ中的羟基发生酯化反应,得到目标化合物Ⅰd,反应在二氯甲烷、四氢呋喃或N,N-二甲基甲酰胺中进行,反应温度为20~80℃,缩合剂选用N,N′-二环己基碳二亚胺、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐或1-羟基苯并三唑;
合成路线:
其中:NR1R2、n的定义与权利要求1相同。
4.根据权利要求1所述的吲哚-3-苄胺衍生物在制备治疗H3受体相关疾病药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910157125 CN101747321B (zh) | 2009-12-22 | 2009-12-22 | 吲哚-3-苄胺衍生物及制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910157125 CN101747321B (zh) | 2009-12-22 | 2009-12-22 | 吲哚-3-苄胺衍生物及制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101747321A CN101747321A (zh) | 2010-06-23 |
CN101747321B true CN101747321B (zh) | 2013-01-02 |
Family
ID=42474998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200910157125 Expired - Fee Related CN101747321B (zh) | 2009-12-22 | 2009-12-22 | 吲哚-3-苄胺衍生物及制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101747321B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1368969A (zh) * | 1999-06-04 | 2002-09-11 | 阿尔米雷尔普罗迪斯制药有限公司 | 作为抗组胺剂和抗过敏剂的吲哚基哌啶衍生物 |
WO2008095823A1 (en) * | 2007-02-07 | 2008-08-14 | F. Hoffmann-La Roche Ag | 5 -amido- (ih- indol- 2 -yl) piperazin-1-yl-methanone derivatives as histamine h3 receptor ligands |
-
2009
- 2009-12-22 CN CN 200910157125 patent/CN101747321B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1368969A (zh) * | 1999-06-04 | 2002-09-11 | 阿尔米雷尔普罗迪斯制药有限公司 | 作为抗组胺剂和抗过敏剂的吲哚基哌啶衍生物 |
WO2008095823A1 (en) * | 2007-02-07 | 2008-08-14 | F. Hoffmann-La Roche Ag | 5 -amido- (ih- indol- 2 -yl) piperazin-1-yl-methanone derivatives as histamine h3 receptor ligands |
Also Published As
Publication number | Publication date |
---|---|
CN101747321A (zh) | 2010-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102295642B (zh) | 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途 | |
JP4958774B2 (ja) | 改変されたピリミジン糖質コルチコイドレセプター調節因子 | |
CN101772487B (zh) | 甲状腺类化合物 | |
RU2637936C2 (ru) | Ингибиторы активности киназы lrrk2 | |
KR20110036609A (ko) | 피페리디닐 gpcr 작용제 | |
IE891662L (en) | Aryl and heteroaryl piperazinyl carboxamides | |
CN102241667B (zh) | 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途 | |
CN1144529A (zh) | 杂环化合物,它们的制备和应用 | |
US20130225633A1 (en) | Phenyl heterocycloalkyl glucocorticoid receptor modulators | |
CN1711249A (zh) | 可用作抗痛觉过敏剂的喹唑啉酮衍生物 | |
JP5193033B2 (ja) | ヒスタミンh3受容体薬剤、製剤及び治療的使用 | |
JP2023554282A (ja) | 置換ピペリジノ化合物及び関連する治療方法 | |
CN107721982B (zh) | 一种抗肥胖症化合物及其制备方法和应用 | |
US20030216379A1 (en) | Substituted fused pyrazolecarboxylic acid arylamides and related compounds | |
CN101747321B (zh) | 吲哚-3-苄胺衍生物及制备方法和用途 | |
US6703393B2 (en) | (Oxo-pyrazolo[1,5a]pyrimidin-2-yl) alkyl-carboxamides | |
CN103025726A (zh) | 作为前列腺素d2受体拮抗剂的取代的嘧啶 | |
US6743817B2 (en) | Substituted fused pyrroleimines and pyrazoleimines | |
CN102112473B (zh) | 吡咯烷基-烷基-酰胺衍生物及其制备方法以及其作为ccr3受体配体的治疗应用 | |
ES2268488T3 (es) | Derivados de 4-imidazol-1-ilmetil-pirimidina como ligandos para receptores de gabaa. | |
CN102869658A (zh) | 脂肪酸酰胺水解酶的调节剂 | |
Minarini et al. | Design, synthesis, and biological evaluation of pirenzepine analogs bearing a 1, 2-cyclohexanediamine and perhydroquinoxaline units in exchange for the piperazine ring as antimuscarinics | |
JPH05201978A (ja) | N−(4,7−ジメトキシ−2−インダニル)−1−(フェニルカルボニル)−n−プロピル−4−ピペリジンメタンアミン誘導体、その製造法および医薬への応用 | |
Jellimann et al. | Melatonergic Properties of the (+)-and (−)-Enantiomers of N-(4-Methoxy-2, 3-dihydro-1 H-phenalen-2-yl) amide Derivatives | |
Tsotinis et al. | Design and synthesis of new N1 and C3-substituted 4-fluoroindolic melatoninergics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130102 Termination date: 20151222 |
|
EXPY | Termination of patent right or utility model |